Literature DB >> 27803081

Renal neuroendocrine tumour and synchronous pancreas metastasis: histopathological diagnosis using prostatic acid phosphatase.

Keishi Kawasaki1,2, Yoshikuni Kawaguchi1,3, Yoshio Suzuki4, Nobutaka Tanaka1.   

Abstract

A woman aged 56 years developed 2 synchronous tumours: one, 1.2 cm in diameter at the head of the pancreas; and the other, 4.0 cm in diameter, at the left side of her horseshoe kidney. Preoperative differential diagnosis of these hypovascular lesions included pancreatic ductal carcinoma (PDC) with renal metastasis, PDC with renal angiomyolipoma, renal cell carcinoma with pancreatic metastasis or PDC and renal cell carcinoma. Following pancreaticoduodenectomy and left nephrectomy, both specimens were diagnosed as grade 2 neuroendocrine tumours (NETs). Immunohistochemistry revealed that both were positive for prostatic acid phosphatase (PAP), which is specific to hindgut-derived NET, including renal NET. Accordingly, the renal tumour was diagnosed as the primary lesion, and the pancreatic tumour as a metastasis. To the best of our knowledge, this is the first report of a renal NET with a synchronous pancreas metastasis. Immunohistochemical staining for PAP was a useful diagnostic marker for synchronous NETs in the kidney and pancreas. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27803081      PMCID: PMC5129108          DOI: 10.1136/bcr-2016-214759

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

Review 1.  Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.

Authors:  Hiu-yan Chan; Ashley B Grossman; Ronald M Bukowski
Journal:  Adv Ther       Date:  2010-07-08       Impact factor: 3.845

2.  Primary carcinoid tumour in horseshoe kidney.

Authors:  Radosław Litwinowicz; Joanna Szpor; Grzegorz Januś; Marek Worek; Krzysztof Okoń
Journal:  Pol J Pathol       Date:  2011       Impact factor: 1.072

Review 3.  The epidemiology of gastroenteropancreatic neuroendocrine tumors.

Authors:  Ben Lawrence; Bjorn I Gustafsson; Anthony Chan; Bernhard Svejda; Mark Kidd; Irvin M Modlin
Journal:  Endocrinol Metab Clin North Am       Date:  2011-03       Impact factor: 4.741

4.  Neuroendocrine hepatic metastases: does aggressive management improve survival?

Authors:  John G Touzios; James M Kiely; Susan C Pitt; William S Rilling; Edward J Quebbeman; Stuart D Wilson; Henry A Pitt
Journal:  Ann Surg       Date:  2005-05       Impact factor: 12.969

5.  Prostatic acid phosphatase in carcinoid tumors. Immunohistochemical and immunoblot studies.

Authors:  N Azumi; S T Traweek; H Battifora
Journal:  Am J Surg Pathol       Date:  1991-08       Impact factor: 6.394

6.  Islet cell tumors of the pancreas: clinical, radiologic, and pathologic correlation in diagnosis and localization.

Authors:  P C Buetow; D L Miller; T V Parrino; J L Buck
Journal:  Radiographics       Date:  1997 Mar-Apr       Impact factor: 5.333

Review 7.  Primary carcinoid tumors of the kidney.

Authors:  Frederico R Romero; Soroush Rais-Bahrami; Sompol Permpongkosol; Samson W Fine; Sahar Kohanim; Thomas W Jarrett
Journal:  J Urol       Date:  2006-12       Impact factor: 7.450

Review 8.  Primary renal carcinoid. Case report and literature review.

Authors:  J R Goldblum; R V Lloyd
Journal:  Arch Pathol Lab Med       Date:  1993-08       Impact factor: 5.534

9.  Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival.

Authors:  T R Halfdanarson; K G Rabe; J Rubin; G M Petersen
Journal:  Ann Oncol       Date:  2008-05-30       Impact factor: 32.976

10.  Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?

Authors:  H Chen; J M Hardacre; A Uzar; J L Cameron; M A Choti
Journal:  J Am Coll Surg       Date:  1998-07       Impact factor: 6.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.